FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria di Stack

Skin Repair Stack

Skin & Hairbeginner

84

sintesi

84
Share
Peptidi

2

Media giornaliera mcg

750

Livello

beginner

Aggiunto

May 17, 2026

Panoramica

The Skin Repair Stack is a focused two-peptide protocol for accelerating skin healing, collagen production, and tissue recovery following damage from procedures, injuries, or chronic conditions. GHK-Cu is arguably the most well-validated peptide for dermatological applications. Its mechanisms in skin include: stimulation of collagen type I and III synthesis (the primary structural proteins of the dermis), promotion of glycosaminoglycan production (hyaluronic acid, dermatan sulfate) for hydration and plumpness, upregulation of integrin expression for cell adhesion and tissue organization, and attraction of macrophages for debris clearance and growth factor secretion. Clinical studies have demonstrated that GHK-Cu-containing products increase skin thickness, reduce fine lines, and improve elasticity within 12 weeks of consistent use. BPC-157 complements GHK-Cu through its unique vascular and growth factor effects. Skin healing requires robust blood supply for nutrient delivery and waste removal, and BPC-157''s documented promotion of angiogenesis (via VEGF upregulation) ensures adequate perfusion of healing tissue. It also modulates multiple growth factors simultaneously — EGF, FGF, and HGF — creating an environment that accelerates all phases of wound healing: inflammation, proliferation, and remodeling. Animal studies demonstrate that BPC-157 treated wounds show earlier collagen deposition, faster re-epithelialization, and improved tensile strength compared to controls. The combination is particularly effective for post-procedure recovery (after laser treatments, chemical peels, microneedling, or surgery), scar remodeling, chronic wound healing, and general skin rejuvenation in aging skin. GHK-Cu provides the building blocks and instructions for tissue reconstruction, while BPC-157 ensures the infrastructure (blood supply) and growth factor environment support rapid, high-quality repair. The beginner classification reflects the simplicity of the two-compound protocol, the extensive safety literature on both peptides, and the straightforward dosing schedule. Topical GHK-Cu can be applied directly to target areas for localized effects, while subcutaneous BPC-157 provides systemic support.

Protocollo di Dosaggio

GHK-Cu

Every day· topical/subcutaneous

Leggi di più su GHK-Cu →

500 mcg

per dose

BPC-157

Every day· subcutaneous

Leggi di più su BPC-157 →

250 mcg

per dose

Obiettivi & Evidenze

Skin repairCollagen synthesisWound healingPost-procedure recoveryScar reduction
Livello di Evidenza:Dati umani

Avvertenze

  • BPC-157 was removed from the FDA Category 2 list (April 2026) but remains under PCAC review (July 23, 2026) — removal is not approval; not legal to compound yet.

Comments

Sign in to join the discussion

Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.